Skip to main content
Home
Issues
2023
June 2023 - Vol 16 No 1
2022
December - Vol 15 No 4
September - Vol 15 No 3
June - Vol 15 No 2
March - Vol 15 No 1 - Online Only
Issue Archive
Special Issues
December 2023 Vol 16, Payers' Guide to FDA Updates
Supplements
Special Issue Archive
Topics
Conference Correspondent
ESMO 2023 - Small Cell Lung Cancer
Web Exclusives
Web Exclusive Topics
All Web Exclusives
Select Drug Profiles
FDA Approvals
In the News
Press Releases
Videos
Interview with the Innovators
About
About AHDB
Contact Us
Permissions
Editorial Policies
Editorial Board
Editorial Process
Advertising Contacts
Advertising Policy
Reprints
Subscribe
Home
Issues
2023
June 2023 - Vol 16 No 1
2022
December - Vol 15 No 4
September - Vol 15 No 3
June - Vol 15 No 2
March - Vol 15 No 1 - Online Only
Issue Archive
Special Issues
December 2023 Vol 16, Payers' Guide to FDA Updates
Supplements
Special Issue Archive
Topics
Conference Correspondent
ESMO 2023 - Small Cell Lung Cancer
Web Exclusives
Web Exclusive Topics
All Web Exclusives
Select Drug Profiles
FDA Approvals
In the News
Press Releases
Videos
Interview with the Innovators
About
About AHDB
Contact Us
Permissions
Editorial Policies
Editorial Board
Editorial Process
Advertising Contacts
Advertising Policy
Reprints
Conference Correspondent
News, views, and coverage of important topics and discussions from oncology conferences and events.
[widgetkit id="1" name="CC Event Nav"]
Third Interim Analysis from the Phase 2 Vision HO141 Trial of Venetoclax + Ibrutinib for Patients with R/R CLL: 15-Month Safety, Response, and MRD Evaluation
Read More
Phase 2 Results of the iR2 Regimen (Ibrutinib, Lenalidomide, and Rituximab) in Patients with Relapsed/Refractory Non-GCB DLBCL
Read More
Bruton’s Tyrosine Kinase Inhibitor Zanubrutinib (BGB-3111) in Patients with CLL/SLL: Updated Results from a Phase 1/2 Trial
Read More
Zanubrutinib in Patients with Treatment-Naïve CLL/SLL with Del(17p): Initial Results from Arm C of the Sequoia (BGB-3111-304) Trial
Read More
Four-Year Analysis of MURANO Study, Evaluating Fixed-Duration Venetoclax + Rituximab in Relapsed/Refractory Chronic Lymphocytic Leukemia
Read More
Pooled Analysis of Ibrutinib versus Prior Regimen in Relapsed/Refractory Mantle-Cell Lymphoma with up to 7.5 Years of Extended Follow-Up
Read More
Alliance A041702 Phase 3 Study Comparing Ibrutinib + Obinutuzumab versus Ibrutinib + Venetoclax + Obinutuzumab in Untreated, Older Patients with CLL
Read More
Ixazomib, Rituximab, and Dexamethasone in Patients with Relapsed or Progressive Waldenström Macroglobulinemia
Read More
Ibrutinib, Fludarabine, Cyclophosphamide, and Obinutuzumab for First-Line Treatment of CLL with IGHV Mutation and without Del(17p)/Mutated TP53
Read More
Ibrutinib + Rituximab versus FCR in Younger Patients with CLL: Extended Follow-Up of E1912 Trial
Read More
1
2
3
4
5
6
Page 3 of 25
Results 21 - 30 of 242